38
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Uveitis Seroreactivity to Candidate pANCA Antigens: Mycobacterial HupB and Histone H1(69-171)

, , , &
Pages 191-198 | Accepted 14 Apr 2004, Published online: 08 Jul 2009
 

Abstract

Purpose: Certain uveitis patients express the disease-marker antibody pANCA. Histone H1 (H1) and mycobacterial HupB (HupB) are recently identified candidate pANCA antigens. This study addresses the hypothesis that H1 and HupB are targets of disease-associated seroreactivity in pANCA+ uveitis. Methods: Sera from 293 uveitis patients were categorized for pANCA activity. H1(69-171) and HupB recombinant proteins were used as antigenic targets in ELISA studies. Selected sera were analyzed for reactivity by Western blot. Results: Seroreactivities to ANCA, H1(69-171), and HupB were frequently detected in uveitis patients. No significant relationship existed between the level of ANCA antibody and reactivity to either recombinant antigen. There was, however, a significant, positive correlation between H1(69-171) and HupB seroreactivities. Conclusions: Correlation between H1(69-171) and HupB reactivities suggests the presence of a shared dominant epitope, which is recognized by antibodies in a substantial number of uveitis patients. Seroreactivities to ANCA and HupB/H1 are independent immunologic markers that may identify biologically distinctive subsets of uveitis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.